📰 Johan Dalsgaard News
Page 3 - Johan Dalsgaard News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Johan Dalsgaard. Real-time updates on events, politics, business and more.
April 21, 2022
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company, today announces the first patient enrolled in the pilot...
March 9, 2022
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the Angiotensin II type 2...
March 9, 2022
- Strong preclinical data shows that C21 reverses vascular remodelling - Proof-of-concept trial in pulmonary arterial hypertension ("PAH") planned to start late 2022 - Appointment
March 9, 2022
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the Angiotensin II type 2...
March 9, 2022
Vicore strengthens rare lung disease pipeline with PAH indication - read this article along with other careers information, tips and advice on BioSpace
March 4, 2022
GOTHENBURG, Sweden, March 4, 2022 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2
February 23, 2022
The new AT2R agonist C106, with patent protection to 2041, is ready to enter a phase 1 trial Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022 R&D-day
February 23, 2022
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...
February 23, 2022
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...
February 10, 2022
/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2...